Replies to post #292923 on Avid Bioservices Inc (CDMO)

[Protector]

jbainseky, I will not reply to the PPS and volume part of your post but to your statement:

But note that this procedure is very unique because it isolates tumor exosomes as opposed other methods that isolate/concentrate all exosomes in a sample.

Yo are 100% correct with this observation. And there is an explanation of WHY the PPHM (UTSW) technology can do this.

PPHM had already established the relation of increased levels of PS in the bloodstream when a tumour existed somewhere. The idea was that ON TOP of the PS coming from apoptosis there would be EXTRA PS in the blood stream coming from the damaged endothelial cells there were the tumour is.

So if you look for micro vesicles that hold PS + your target molecule you can not only count the target molecule to evaluate it against a scale but you can FIRST, based on your PS count, decide if there is a tumor or not. If not all molecule count is useless (and that is what the others do) because it might not be cancer related.

For instance during a VIRAL problem the amount of PS can be EXTREMELY high, masking tumours but ALSO indicating that the molecule count should be analysed with care because it is probably NOT cancer but viral related.

So PPHM fist looks at PS and based on PS scaling then counts target molecules. PS allows to find out the STAGE and monitor progression/regression during treatment.


The Practical and moneytisable advantage of all this is that PPHM does NOT have to handle mutations over time (as do DNA based techniques), will have very few to no false positives/negatives, is a COMPLETE TEST as needed to tap in said 100-200Bil$ market in cancer diagnostics and it is SIMPLE, FAST and CHEAP (which cannot be said of all non-blood test based tests and very often also not of many blood test based test because they need centrifugal activities).